Management and prognosis of tricuspid regurgitation

INTRODUCTION

Tricuspid regurgitation (TR) is a relatively common abnormality. Since this lesion is frequently asymptomatic and may not be detected on physical examination, it is often diagnosed solely by echocardiography. This topic will review the prognosis and management of tricuspid regurgitation.

Etiology, clinical features, and evaluation of tricuspid regurgitation are discussed separately. (See "Etiology, clinical features, and evaluation of tricuspid regurgitation".)

PROGNOSIS

Most cases of TR in adults are functional, with a minority of cases due to primary acquired or congenital valve disease. Functional TR is commonly associated with left-sided heart disease, particularly mitral valve disease and/or left heart failure. (See "Etiology, clinical features, and evaluation of tricuspid regurgitation", section on 'Etiology'.) Acquired cause of TR in adults includes endocarditis, traumatic flail leaflet, and impingement of pacer leads on tricuspid valve closure.

Most cases of TR due to valve disease in adolescents and young adults are congenital, with Ebstein's anomaly being most common [1]. (See "Ebstein's anomaly of the tricuspid valve".)

While the clinical setting (particularly concomitant cardiovascular disease) influences survival in patients with TR, severe TR is an independent predictor of mortality as illustrated by the following studies:

               

Subscribers log in here

To continue reading this article, you must log in with your personal, hospital, or group practice subscription. For more information or to purchase a personal subscription, click below on the option that best describes you:
Literature review current through: Jun 2014. | This topic last updated: Aug 14, 2013.
The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use ©2014 UpToDate, Inc.
References
Top
  1. Guenther T, Noebauer C, Mazzitelli D, et al. Tricuspid valve surgery: a thirty-year assessment of early and late outcome. Eur J Cardiothorac Surg 2008; 34:402.
  2. Nath J, Foster E, Heidenreich PA. Impact of tricuspid regurgitation on long-term survival. J Am Coll Cardiol 2004; 43:405.
  3. Koelling TM, Aaronson KD, Cody RJ, et al. Prognostic significance of mitral regurgitation and tricuspid regurgitation in patients with left ventricular systolic dysfunction. Am Heart J 2002; 144:524.
  4. Lee JW, Song JM, Park JP, et al. Long-term prognosis of isolated significant tricuspid regurgitation. Circ J 2010; 74:375.
  5. Hamilton MA, Stevenson LW, Child JS, et al. Sustained reduction in valvular regurgitation and atrial volumes with tailored vasodilator therapy in advanced congestive heart failure secondary to dilated (ischemic or idiopathic) cardiomyopathy. Am J Cardiol 1991; 67:259.
  6. Song JM, Kang DH, Song JK, et al. Outcome of significant functional tricuspid regurgitation after percutaneous mitral valvuloplasty. Am Heart J 2003; 145:371.
  7. Hannoush H, Fawzy ME, Stefadouros M, et al. Regression of significant tricuspid regurgitation after mitral balloon valvotomy for severe mitral stenosis. Am Heart J 2004; 148:865.
  8. Shafie MZ, Hayat N, Majid OA. Fate of tricuspid regurgitation after closed valvotomy for mitral stenosis. Chest 1985; 88:870.
  9. Sadeghi HM, Kimura BJ, Raisinghani A, et al. Does lowering pulmonary arterial pressure eliminate severe functional tricuspid regurgitation? Insights from pulmonary thromboendarterectomy. J Am Coll Cardiol 2004; 44:126.
  10. Kim YJ, Kwon DA, Kim HK, et al. Determinants of surgical outcome in patients with isolated tricuspid regurgitation. Circulation 2009; 120:1672.
  11. Scully HE, Armstrong CS. Tricuspid valve replacement. Fifteen years of experience with mechanical prostheses and bioprostheses. J Thorac Cardiovasc Surg 1995; 109:1035.
  12. Carrier M, Hébert Y, Pellerin M, et al. Tricuspid valve replacement: an analysis of 25 years of experience at a single center. Ann Thorac Surg 2003; 75:47.
  13. Marquis-Gravel G, Bouchard D, Perrault LP, et al. Retrospective cohort analysis of 926 tricuspid valve surgeries: clinical and hemodynamic outcomes with propensity score analysis. Am Heart J 2012; 163:851.
  14. Bonow RO, Cheitlin MD, Crawford MH, Douglas PS. Task Force 3: valvular heart disease. J Am Coll Cardiol 2005; 45:1334.
  15. Vahanian A, Baumgartner H, Bax J, et al. Guidelines on the management of valvular heart disease: The Task Force on the Management of Valvular Heart Disease of the European Society of Cardiology. Eur Heart J 2007; 28:230.
  16. Moraca RJ, Moon MR, Lawton JS, et al. Outcomes of tricuspid valve repair and replacement: a propensity analysis. Ann Thorac Surg 2009; 87:83.
  17. Ghanta RK, Chen R, Narayanasamy N, et al. Suture bicuspidization of the tricuspid valve versus ring annuloplasty for repair of functional tricuspid regurgitation: midterm results of 237 consecutive patients. J Thorac Cardiovasc Surg 2007; 133:117.
  18. McCarthy PM, Bhudia SK, Rajeswaran J, et al. Tricuspid valve repair: durability and risk factors for failure. J Thorac Cardiovasc Surg 2004; 127:674.
  19. Navia JL, Nowicki ER, Blackstone EH, et al. Surgical management of secondary tricuspid valve regurgitation: annulus, commissure, or leaflet procedure? J Thorac Cardiovasc Surg 2010; 139:1473.
  20. Singh SK, Tang GH, Maganti MD, et al. Midterm outcomes of tricuspid valve repair versus replacement for organic tricuspid disease. Ann Thorac Surg 2006; 82:1735.
  21. Fukuda S, Song JM, Gillinov AM, et al. Tricuspid valve tethering predicts residual tricuspid regurgitation after tricuspid annuloplasty. Circulation 2005; 111:975.
  22. Dreyfus GD, Raja SG, John Chan KM. Tricuspid leaflet augmentation to address severe tethering in functional tricuspid regurgitation. Eur J Cardiothorac Surg 2008; 34:908.
  23. Ratnatunga CP, Edwards MB, Dore CJ, Taylor KM. Tricuspid valve replacement: UK Heart Valve Registry mid-term results comparing mechanical and biological prostheses. Ann Thorac Surg 1998; 66:1940.
  24. Van Nooten GJ, Caes F, Taeymans Y, et al. Tricuspid valve replacement: postoperative and long-term results. J Thorac Cardiovasc Surg 1995; 110:672.
  25. Do QB, Pellerin M, Carrier M, et al. Clinical outcome after isolated tricuspid valve replacement: 20-year experience. Can J Cardiol 2000; 16:489.
  26. Sung K, Park PW, Park KH, et al. Is tricuspid valve replacement a catastrophic operation? Eur J Cardiothorac Surg 2009; 36:825.
  27. Filsoufi F, Anyanwu AC, Salzberg SP, et al. Long-term outcomes of tricuspid valve replacement in the current era. Ann Thorac Surg 2005; 80:845.
  28. Rizzoli G, Vendramin I, Nesseris G, et al. Biological or mechanical prostheses in tricuspid position? A meta-analysis of intra-institutional results. Ann Thorac Surg 2004; 77:1607.
  29. Shrestha BM, Fukushima S, Vrtik M, et al. Partial replacement of tricuspid valve using cryopreserved homograft. Ann Thorac Surg 2010; 89:1187.
  30. O'Brien SM, Shahian DM, Filardo G, et al. The Society of Thoracic Surgeons 2008 cardiac surgery risk models: part 2--isolated valve surgery. Ann Thorac Surg 2009; 88:S23.
  31. Ambler G, Omar RZ, Royston P, et al. Generic, simple risk stratification model for heart valve surgery. Circulation 2005; 112:224.
  32. Roques F, Nashef SA, Michel P, et al. Risk factors and outcome in European cardiac surgery: analysis of the EuroSCORE multinational database of 19030 patients. Eur J Cardiothorac Surg 1999; 15:816.
  33. Nashef SA, Roques F, Michel P, et al. European system for cardiac operative risk evaluation (EuroSCORE). Eur J Cardiothorac Surg 1999; 16:9.
  34. Bonow RO, Carabello BA, Chatterjee K, et al. 2008 Focused update incorporated into the ACC/AHA 2006 guidelines for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1998 Guidelines for the Management of Patients With Valvular Heart Disease): endorsed by the Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. Circulation 2008; 118:e523.